+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06191263

Evaluating Safety, Dose, and Effectiveness of RVU120 Combined with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Led by Ryvu Therapeutics SA · Updated on 2026-09-18

98

Participants Needed

37

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the combination of RVU120 and venetoclax in adults with acute myeloid leukemia AML that has returned or not responded to prior treatment with venetoclax and a hypomethylating agent. This Phase 2 trial aims to determine safe and tolerated doses, assess the treatments safety and effectiveness, and confirm these findings in a larger group of patients. Participants receive oral doses of RVU120 every other day and venetoclax daily in 21-day cycles. The study has three parts Part 1 involves dose escalation to find safe doses Part 2 evaluates safety and response at these doses and Part 3 confirms efficacy and safety in more patients using the recommended doses from Part 2. During the study, participants are monitored for safety, treatment response, and drug behavior in the body through regular assessments. Researchers track remission rates, side effects, blood transfusion needs, survival outcomes, and the impact on patient-reported quality of life. The study lasts approximately 36 months with ongoing evaluations throughout the treatment cycles.

CONDITIONS

Brief Title

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Research Team

H

Head of Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here